NGEN
NervGen Pharma Corp.
NASDAQ: NGEN · HEALTHCARE · BIOTECHNOLOGY
$2.19
+1.16% today
Updated 2026-09-11
Market cap
$250.53M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.57
Dividend yield
—
52W range
$2 – $6
Volume
0.6M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C3.8
Quality
D3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-9.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$10.00
+357.67%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -9.40 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-5.81M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-20.54M | $-22.38M | $-23.99M | $-44.12M | $-29.99M |
| EPS | — | — | — | — | $-0.57 |
| Free cash flow | $-17.65M | $-11.30M | $-16.83M | $-19.50M | $-5.81M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
NervGen Pharma Corp. trades at $2.19. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -9.40, it sits in the distress.
Frequently asked questions
What is NervGen Pharma Corp.'s stock price?
NervGen Pharma Corp. (NGEN) trades at $2.19.
Is NervGen Pharma Corp. overvalued?
NervGen Pharma Corp. carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of NervGen Pharma Corp. (NGEN)?
The 12-month analyst consensus target is $10.00, about 357.7% above the current $2.19. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
NervGen Pharma Corp.'s Altman Z-Score is -9.40, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-1,207.00%
Beta0.73
50D MA$1.86
200D MA$3.38
Shares out0.11B
Float0.10B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—